Figure 6

Figure 6

(A) Effect of CPP531 treatment on swim test motility time. *p < 0.05 for significant higher motility time compared to vehicle treated mice (designated as ‘no drug’). (B) Representative images of gastrocnemius muscle inflammation and fiber regeneration (indicated by the presence of small, centrally nucleated fibers) in vehicle treated mice and CPP531 treated mice 7 d after barium chloride injection. Scale bar = 100 µm. (C) Percentage of damaged gastrocnemius muscle tissue after 7 days. *p < 0.05 for significantly reduced damaged tissue compared to vehicle treated mice. (D) Muscle fiber diameter in vehicle treated mice and CPP531 treated mice after 7 d. *p < 0.05 for significantly larger diameter compared to vehicle treated mice. (E) Inflammatory cell count in the gastrocnemius muscle of untreated mice and CPP531 treated mice after 7 d. *p < 0.05 for significantly reduced inflammatory cell count compared to vehicle treated mice. (F) Representative images of the gastrocnemius muscle of untreated and CPP531 treated mice 14 d after barium chloride injection. Scale bar = 100 µm. (G) Percentage of damaged gastrocnemius muscle tissue after 14 d. *p < 0.05 for significantly reduced damaged tissue compared to vehicle treated mice. (H) Muscle fiber diameter in untreated mice and CPP531 treated mice at 14 d. *p < 0.05 for significantly increased diameter compared to vehicle treated mice. (I) Inflammatory cell count in the gastrocnemius muscle of untreated mice and CPP531 treated mice at 14 d. *p < 0.05 for significantly lower inflammatory cell count compared to the vehicle treated mice. n = 5 mice per treatment group.